We are focusing on the research and development of new medicines to help people across the world share the benefits of advancing medical technology. Innovation across all areas of healthcare is the cornerstone of our strategy.
In Novartis, corporate responsibility is divided into two main areas - the extension of access to healthcare and responsible business access.
Novartis provides not only prevention, diagnosis and treatment, but also seeks innovative ways to make healthcare accessible to patients in need. In cooperation with the World Health Organization (WHO) and non-profit organizations, Novartis participates in programs to improve treatment availability in developing countries. More than 8.1 million people around the world took part in the educational activities of our company.
Health education and new treatment options for patients who would otherwise not be able to receive treatment and treatment are provided by our company, for example, in India, through the Arogya Parivar program or Healthy Family. Our company employees in the Indian branch have already organized training and camps for more than 300,000 villages, which is more than 11 million people.
Our next goal is to control and eliminate malaria and leprosy. Malaria affects about 219 million people worldwide and annually kills more than 600,000. We are the first company to supply antimalarials to countries with endemic incidence of these diseases without any sales gain. In autumn 2013, we joined the "Power of One" campaign, which you will learn more about on the project's website.
More about the antimalarial development and the Power of One project: Power of One
We provide not only prevention, diagnosis and treatment, but we also seek new ways to treat illnesses that affect only some areas of the world. Since 2000, in cooperation with the World Health Organization (WHO), we have cured over 5 million leprosy patients. Furthermore, we are trying to develop new ways of treating malaria because current treatment will not be sufficient sooner or later and the parasites will gradually become resistant. We also develop typhus and paratyfus A vaccines. The research and development of these diseases is being carried out at Landing Page research centers.
Responsible approach to business
We approach our business responsibly. We adhere to high ethical standards. Every employee has to go through the Code of Conduct training both on entering the company and repeatedly every other year. All employees also have the opportunity to report suspicions of unethical behavior to the Business Practices Office (BPO), whose representative is working in every branch of the company.
In the field of environmental care, Novartis focuses on the use of renewable energy sources, which make up 40% of our total energy consumption.